Related Experiment Video
Updated: Jul 10, 2025
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Exploring Therapeutic Avenues in Lung Cancer: The Epigenetic Perspective
Raluca Munteanu1,2, Ciprian Tomuleasa1,3,4, Cristina-Adela Iuga5,6
1Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
Abstract:
Lung cancer, primarily non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC), is distinguished by its high prevalence and marked mortality rates. Traditional therapeutic approaches, encompassing chemotherapy, radiation, and targeted therapies, frequently show limited efficacy due to acquired resistance and notable side effects. The objective of this review is to introduce a fresh perspective on the therapeutic strategies for lung cancer, emphasizing interventions targeting the epigenetic alterations often seen in this malignancy. This review presents the most recent advancements in the field, focusing on both past and current clinical trials related to the modulation of methylation patterns using diverse molecular agents. Furthermore, an in-depth analysis of the challenges and advantages of these methylation-modifying drugs will be provided, assessing their efficacy as individual treatments and their potential for synergy when integrated with prevailing therapeutic regimens.
Insights
This review explores novel epigenetic therapies for lung cancer, focusing on methylation modulation to overcome treatment resistance and improve outcomes for non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC).
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Lung cancer, including non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC), has high mortality rates.
- Current treatments like chemotherapy and radiation often face limited efficacy due to acquired resistance and side effects.
Purpose of the Study:
- To present a novel perspective on lung cancer therapeutic strategies.
- To emphasize interventions targeting epigenetic alterations, specifically methylation patterns, in lung cancer treatment.
Main Methods:
- Review of recent advancements in epigenetic modulation of methylation patterns.
- Analysis of past and current clinical trials involving molecular agents targeting methylation.
- Assessment of methylation-modifying drugs as monotherapies and in combination regimens.
Main Results:
- Identification of emerging molecular agents for methylation pattern modulation.
- Evaluation of clinical trial data on the efficacy of epigenetic therapies in lung cancer.
- Analysis of challenges and advantages associated with methylation-modifying drugs.
Conclusions:
- Epigenetic interventions, particularly methylation modulation, offer a promising new avenue for lung cancer treatment.
- Further research and clinical trials are needed to fully elucidate the potential of these agents in combination therapies for NSCLC and SCLC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:37Epigenetic Regulation
X-chromosome...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...